
by Laurel Fick MD, FACP, DipABLM, MSCP
If you’ve heard that “hormone therapy is dangerous, ” you’re not alone. That fear traces back to early headlines from the Women’s Health Initiative (WHI) study in 2002. But two decades to early headlines from the Women’s Health Initiative (WHI) study in 2002. But two decadesof follow-up, re-analyses, and modern prescribing have clarified what those headlines missed:
For most healthy women who start hormone therapy before age 60 or within ~10 years oftheir final period, estrogen therapy is highly effective for symptoms (Lippincott Journals)and demonstrates multiple healthy aging benefits.
During the menopause transition, estrogen levels fall and fluctuate. Estrogen is not just a “reproductive hormone”-- it has receptors throughout the body, including the brain, bloodvessels, skin, joints, and bone. That’s why menopause can affect more than periods.
When appropriately prescribed, menopausal hormone therapy (MHT)—often simply called “HRT”—can help with:
● Hot flashes and night sweats (vasomotor symptoms) – this is where estrogen is most consistently effective (PubMed)
● Vaginal dryness, discomfort with sex, urinary symptoms (genitourinary syndrome of menopause) (PubMed)
● Bone loss and fracture risk (estrogen helps maintain bone density) (PubMed)
WHI was a landmark randomized trial, but it was widely misapplied.
Key context that many headlines skipped:
1. The average participant was ~63 years old, and many were more than 10 years past menopause—not the typical person starting therapy for new hot flashes in her early 50s. (PMC)
2. The main regimen studied was oral conjugated equine estrogen (CEE) with medroxyprogesterone acetate (MPA) for women with a uterus—specificformulations that aren’t the only (or most common) choices today. (PMC)
3. Later analyses showed risks and benefits vary strongly by age and time-since-menopause (often called the “timing hypothesis”). In younger womencloser to menopause, absolute risks were much lower and overall outcomes were more favorable than in older starters. (PMC)
So why did HRT get a bad rap? Because early reports often sounded like a universal warning—when the real story was “it depends who starts, when, and what they take.”
What’s well supported:
● Best treatment for hot flashes/night sweats and quality-of-life symptoms. (PubMed)
● Bone protection while on therapy. (PubMed)
● Lower absolute risk in healthy women who start younger/earlier, especially when therapy is individualized (dose, route, and formulation). (AHA Journals)
What’s not fully known (yet):
● Estrogen therapy may also support healthy aging in the brain, metabolic health, and reduce risks of chronic health conditions
Hormone therapy is not “risk free,” but the risks are often small in absolute numbers for appropriately selected patients.
A few key safety points:
● If you have a uterus, estrogen must be paired with uterine protection (a progestogensuch as micronized progesterone, or other clinician-recommended options). This reduces the risk of uterine (endometrial) cancer. (ACOG)
● Blood clot and stroke risk can vary by route. Many guidelines note that transdermal (patch/gel/spray) estrogen may have a lower clot risk than oral estrogen, making it a preferred option for most women. (Lippincott Journals)
● Breast cancer risk depends on the regimen and duration. In WHI, combined estrogen + progestin showed a different breast risk signal than estrogen-only (used only after hysterectomy), but most modern experts do not think that menopausal hormone therapy is causally related to breast cancer. This is one reason individualized choice of formulation matters. (PMC)
Bottom line: good menopause care is about matching the right patient to the right therapy, at the right time, using the safest effective dose and reassessing periodically. (Lippincott Journals)
If you’re considering hormone therapy, be sure to see a physician or provider that is educated in the care of perimenopause and menopause. You can find local experts using the finder from The Menopause Society.
For the most reliable treatments:
Use FDA-approved options (they are standardized for purity, dose, and safety monitoring):
● Transdermal 17β-estradiol (patch/gel/spray)
● Oral estradiol (in appropriate candidates)
● Micronized progesterone (when uterine protection is needed)
● Low-dose vaginal estrogen for local symptoms (often with minimal systemic absorption)
Avoid “shortcuts” that aren’t supported by strong safety data:
Compounded “bioidentical” hormones: not FDA-approved, potency can vary, and claims based on saliva testing are not reliable. (ACOG)
Hormone pellets: dosing is difficult to adjust once placed, and they’re frequently compounded/unregulated; mainstream guidelines generally prefer adjustable,FDA-approved routes. (If someone is pushing pellets as “safer,” ask for high-quality evidence—not marketing.) (ACOG)

Dr. Laurel Fick is the CEO and Founder of Niche Medical at InFitness Club in Indianapolis, IN. Dr. Fick worked as an academic Internal Medicine physician at a large, local hospital system for over 15 years before opening her practice. Dr. Fick is double boarded in Internal Medicine and Lifestyle Medicine and is a Menopause Society Certified Practitioner whose practice emphasizes whole human health. Her focus on prevention, risk stratification, and lifestyle medicine aims to partner with patients in optimizing their health for decades of disease-free living and thriving.